### CADTH DRUG REIMBURSEMENT REVIEW

# Pharmacoeconomic Report

Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy)

(Bristol-Myers Squibb)

**Indication:** First-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no known EGFR or ALK genomic tumour aberrations.

Version:FinalPublication Date:March 4, 2021Report Length:16 Pages

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.



### **Table of Contents**

4
5
6
8
9
10
11
12
13
ne
14
15
16



#### **List of Tables**

Table 1: Submitted for Review	6
Table 2: Summary of Economic Evaluation	7



#### **Abbreviations**

AIC	Akaike information criterion
ALK	anaplastic lymphoma kinase
BIC	Bayesian information criterion
DoT	duration on treatment
EGFR	epidermal growth factor receptor
ICER	incremental cost-effectiveness ratio
KM	Kaplan-Meier
LY	life-year
Mb	megabase
mg	milligram
NI+PDC	nivolumab in combination with ipilimumab and two cycles of platinum-based chemotherapy
NSCLC	non-small cell lung cancer
OS	overall survival
PDC	platinum-doublet chemotherapy
PD-L1	programmed death ligand-1
PEM	pembrolizumab
PFS	progression-free survival
QALY	quality-adjusted life-year

**Executive Summary** The executive summary is comprised of two tables (Table 1 and Table 2) and a conclusion.

Table 1: Submitted f	
Item	Description
Drug product	Nivolumab (Opdivo; single-use vial for injection), to be used in combination with ipilimumab (Yervoy; vial for injection) and two cycles of platinum-based chemotherapy
Submitted prices	Nivolumab, 10 mg per mL, solution: \$19.55 per mg (\$782.22 per 40 mg vial)
	Nivolumab, 10 mg per mL, solution: \$19.55 per mg (\$1955.56 per 100 mg vial)
	Ipilimumab, 5 mg per mL, solution: \$116.00 per mg (\$5800.00 per 50 mg vial)
Indication	Adult patients with metastatic non-small cell lung cancer (NSCLC) with no known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations and no prior systemic therapy for metastatic NSCLC.
Health Canada approval status	NOC
Health Canada review pathway	Other expedited pathway – Project Orbis
NOC date	August 6, 2020
Reimbursement request	As per indication
Sponsor	Bristol-Myers Squibb Company
Submission history	Previously reviewed: Yes (nivolumab plus ipilimumab) Indication: patients with intermediate or poor-risk advanced renal-cell carcinoma based on the International Metastatic Renal Cell Carcinoma Database Consortium Recommendation date: November 1, 2018 Recommendation: Recommended with a price reduction to improve the cost-effectiveness of nivolumab to an acceptable level.
	Previously reviewed: Yes (nivolumab plus ipilimumab) Indication: patients with unresectable or metastatic melanoma regardless of BRAF status who are treatment-naïve, with ECOG performance status 0 – 1 and with stable rain metastases, if present Recommendation date: November 30, 2017 Recommendation: Recommended with a price reduction to improve the cost-effectiveness of nivolumab to an acceptable level.
	Previously reviewed: Yes (nivolumab) Indication: adults with advanced or metastatic NSCLC who progressed on or after chemotherapy Recommendation date: June 3, 2016 Recommendation: Recommended with a price reduction to improve the cost-effectiveness of nivolumab to an acceptable level.

ALK = anaplastic lymphoma kinase; BRAF = gene mutation; ECOG = Eastern Cooperative Oncology Group; EGFR = epidermal growth factor receptor; NSCLC = nonsmall cell lung cancer

Type of economic evaluation         Cost-utility analysis           Partitioned survival model         Partitioned survival model           Target population         Adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations           Treatments         Nivolumab in combination with ipilimumab and two cycles of platinum-based chemotherapy (NI+PDC)           Comparators         • platinum-doublet chemotherapy (PCC) comprising carboplatin + pacifitaxel for squamous histology, and for non-squamous histology, carboplatin + pacifitaxel for squamous histology comprising carboplatin + pemetrexed or cisplatin + pemetrexed (PEM+PDC)           • pembrolizumab in combination with PDC for non-squamous histology comprising carboplatin + pemetrexed or cisplatin + pemetrexed (PEM+PDC)           • pembrolizumab in combination with carboplatin + pacifitaxel or nab-pacifitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + pacifitaxel or nab-pacifitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + pacifitaxel or nab-pacifitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + pacifitaxel or nab-pacifitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + pacifitaxel or nab-pacifitaxel for squamous histology (PEM+CHEM)           • perspective         Caradian publicly funded health care payer           Outcomes         QAL		y of Economic Evaluation
evaluation         Partitioned survival model           Target population         Aduit patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations           Treatments         Nivolumab in combination with ipilimumab and two cycles of platinum-based chemotherapy (NI+PDC)           Comparators         • platinum-doublet chemotherapy (PDC) comprising carboplath + pemetrexed           • pembrolizumab in combination with PDC for non-squamous histology comprising carboplath + pemetrexed           • pembrolizumab monotherapy for programmed death ligand 1 (PD-L1) was greater than or equal to 50% (PEM)           • pembrolizumab in combination with carboplatin + pacilitaxel or nab-pacilitaxel for squamous histology (PEM+CHEM)           Perspective         Canadian publicly funded health care payer           Outcomes         OALYs, LYs           Time horizon         Lifetime (20 years)           Key data sources         ObsecMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)           Submitted results         • Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effectiveness ratio when compared to the previous cost-effective treatment and the next more effective treatment)           • NI+PDC is not among the optimal therapies (i.e., not on the efficiency fontiler) <th></th> <th>Description</th>		Description
Target population         Aduit patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations           Treatments         Nivolumab in combination with ipilimumab and two cycles of platinum-based chemotherapy (NI+PDC)           Comparators         9 patinum-doublet chemotherapy (PDC) comprising carboplatin + pemetrexed or cisplatin + pemetrexed (PEM+PDC)           • pembrolizumab in combination with PDC for non-squamous histology comprising carboplatin + pemetrexed (PEM+PDC)           • pembrolizumab in combination with carboplatin + paclitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + paclitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + paclitaxel or nab-paclitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + paclitaxel or nab-paclitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + paclitaxel or nab-paclitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + paclitaxel or nab-paclitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + paclitaxel or nab-paclitaxel for squamous histology (PEM+CHEM)           • Duration         Lifetime (20 years)           • Time horizon         Lifetime (20 years)<		
growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations           Treatments         Nivolumab in combination with iplilimumab and two cycles of platinum-based chemotherapy (NI+PDC)           Comparators         • platinum-doublet chemotherapy (PDC) comprising carboplatin + pemetrexed or cisplatin + pemetrexed or cisplatin + pemetrexed or cisplatin + pemetrexed or cisplatin + pemetrexed (PEM+PDC)           • pembrolizumab in combination with PDC for non-squamous histology comprising carboplatin + pemetrexed (PEM+PDC)           • pembrolizumab in combination with carboplatin + paclitaxel for squamous histology (PEM+CHEM)           • pembrolizumab in combination with carboplatin + paclitaxel for squamous histology (PEM+CHEM)           • Dembrolizumab in combination with carboplatin + paclitaxel for squamous histology (PEM+CHEM)           • Dembrolizumab in combination with carboplatin + paclitaxel for squamous histology (PEM+CHEM)           • Dembrolizumab in combination with carboplatin + paclitaxel for squamous histology (PEM+CHEM)           • Dembrolizumab in combination with carboplatin + paclitaxel for squamous histology (PEM+CHEM)           • Dutationes         QALYs, LYs           • Time horizon         Lifetime (20 years)           Key data sources         CheckMate 9L Arial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)           • Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QLYs compared to PEM+PDC.      <		Partitioned survival model
Comparators       • platinum-doublet chemotherapy (PDC) comprising carboplatin + pacitaxel for squamous histology, and for non-squamous histology, carboplatin + pemetrexed or cisplatin + pemetrexed         • pembrolizumab in combination with PDC for non-squamous histology comprising carboplatin + pemetrexed or cisplatin + pemetrexed (PEM+PDC)         • pembrolizumab monotherapy for programmed death ligand 1 (PD-L1) was greater than or equal to 50% (PEM)         • pembrolizumab in combination with carboplatin + paciltaxel or nab-paciltaxel for squamous histology (PEM+CHEM)         • pembrolizumab in combination with carboplatin + paciltaxel or nab-paciltaxel for squamous histology (PEM+CHEM)         • pembrolizumab in combination with carboplatin + paciltaxel or nab-paciltaxel for squamous histology (PEM+CHEM)         • Dutcomes       QALYs, LYS         Time horizon       Lifetime (20 years)         Key data sources       CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)         • Submitted results       • Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.         • NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effective treatment)       • NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)         Key limitations       • The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be i	Target population	
and for non-squamous histology, carboplatin + permetrexed or cisplatin + permetrexed         epembrolizumab in combination with PDC for non-squamous histology comprising carboplatin + permetrexed or cisplatin + permetrexed (PEM+PDC)         epembrolizumab monotherapy for programmed death ligand 1 (PD-L1) was greater than or equal to 50% (PEM)         epembrolizumab in combination with carboplatin + paciltaxel or nab-paciltaxel for squamous histology (PEM+CHEM)         Perspective       Canadian publicly funded health care payer         Outcomes       QALYs, LYs         Time horizon       Lifetime (20 years)         Key data sources       CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)         Submitted results       e Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.         NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effective treatment)       NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effective treatment)         NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)       The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.         Outration on treatment (DoT) in the model was assumed to equal each t	Treatments	Nivolumab in combination with ipilimumab and two cycles of platinum-based chemotherapy (NI+PDC)
pemetrexed or cisplatin + pemetrexed (PEM+PDC)         • pembrolizumab monotherapy for programmed death ligand 1 (PD-L1) was greater than or equal to 50% (PEM)         • pembrolizumab in combination with carboplatin + paclitaxel or nab-paclitaxel for squamous histology (PEM+CHEM)         Perspective       Canadian publicly funded health care payer         Outcomes       QALYs, LYs         Time horizon       Lifetime (20 years)         Key data sources       CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)         Submitted results       • Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.         • NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effective reast reatment)         • NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)         Key limitations       • The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from ChickMate 9LA.         • Duration on treatment (DOT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from Clinical Review. It is unclear whether outcomes for patients from CheckMate 9LA.         • Duration on treatment (DOT) in the model was assumed to equal each treatment. <th>Comparators</th> <th>and for non-squamous histology, carboplatin + pemetrexed or cisplatin + pemetrexed</th>	Comparators	and for non-squamous histology, carboplatin + pemetrexed or cisplatin + pemetrexed
50% (PEM)         • pembrolizumab in combination with carboplatin + paclitaxel or nab-paclitaxel for squamous histology (PEM+CHEM)         Perspective       Canadian publicly funded health care payer         Outcomes       QALYs, LYs         Time horizon       Lifetime (20 years)         Key data sources       CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)         Submitted results       • Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.         • NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effective reast ratio when compared to the previous cost-effective treatment and the next more effective treatment)         • NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)         Key limitations       • The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.         • Duration on treatment (DOT) in the model was assumed to equal each treatment's PFS curve. Trial- observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicate that PFS provides an overestimation of the duration on treatment.         • For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 227 was applied for the remainder of		pemetrexed or cisplatin + pemetrexed (PEM+PDC)
(PEM+CHEM)           Perspective         Canadian publicly funded health care payer           Outcomes         QALYs, LYs           Time horizon         Lifetime (20 years)           Key data sources         CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)           Submitted results for base case         • Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.           • NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effectiveness ratio when compared to the previous cost-effective treatment and the next more effective treatment)           • NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)           Key limitations         • The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative ada from CheckMate 9LA.           • Duration on treatment (DoT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicate that PFS provides an overestimation of the duration on treatment.           • For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 9LA.           • Duration on treatment, outcomes for patients from CheckMate 227 can be generalized to represent long term		
Outcomes         QALYs, LYs           Time horizon         Lifetime (20 years)           Key data sources         CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)           Submitted results for base case         Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.           • NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effective resatment)         • NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)           Key limitations         • The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.           • Duration on treatment (DOT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicate that PFS provides an overestimation of the duration on treatment.           • For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 927 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is unclear whether outcomes for patients from CheckMate 92.4           • A weight-based approach for nivolumab was applied based on time to mortality data from the CheckMate 227 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is u		F - · · · · · · · · · · · · · · · · · ·
Time horizon         Lifetime (20 years)           Key data sources         CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)           Submitted results for base case         E Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.           • NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effectiveness ratio when compared to the previous cost-effective treatment and the next more effective treatment)           • NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)           Key limitations         • The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.           • Duration on treatment (DOT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicate that PFS provides an overealls unvival (OS) was modeled based on time to mortality data from the CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 227 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is unclear whether outcomes for patients in CheckMate 227 can be generalized to represent long term treatment outcomes for patients in CheckMate 227 can be generalized to represent long term treatment outcomes for patients in CheckMate 227 can be generalized to represent long t	Perspective	Canadian publicly funded health care payer
Key data sources         CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)           Submitted results for base case         • Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.           • NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effective treatment)           • NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)           Key limitations         • The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.           • Duration on treatment (DoT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicate that PFS provides an overestimation of the duration on treatment.           • For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 9LA study, it is unclear whether outcomes for patients from CheckMate 9LA.           • A weight-based approach for nivolumab was applied based on the sponsor's assumed dosing regime of 4.5 mg per kg along with an assumption of 5% vial sharing for nivolumab and ipilimumab. The modeled dosage and vial sharing assumption of 5% vial sharing for nivolumab broduct monograph ar led to an underestimation of the cost per dose of nivolu	Outcomes	QALYs, LYs
Key data sources         CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189, 024, 042, 407)           Submitted results for base case         • Based on the sequential analyses, NI+PDC was more costly and produced more QALYs than PDC, PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.           • NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effective treatment)           • NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)           Key limitations         • The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.           • Duration on treatment (DoT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicate that PFS provides an overestimation of the duration on treatment.           • For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 9LA study, it is unclear whether outcomes for patients from CheckMate 9LA.           • A weight-based approach for nivolumab was applied based on the sponsor's assumed dosing regime of 4.5 mg per kg along with an assumption of 5% vial sharing for nivolumab and ipilimumab. The modeled dosage and vial sharing assumption of 5% vial sharing for nivolumab broduct monograph ar led to an underestimation of the cost per dose of nivolu	Time horizon	Lifetime (20 years)
for base case       PEM, and PEM+CHEM, but was less costly and produced fewer QALYs compared to PEM+PDC.         • NI+PDC was extendedly dominated through PEM and PEM+PDC (i.e., treatment has a higher incremental cost-effective treatment)         • NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)         Key limitations       • The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.         • Duration on treatment (DoT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicated that PFS provides an overestimation of the duration on treatment.         • For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 227 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is unclear whether outcomes for patients from CheckMate 227 can be generalized to represent long term treatment outcomes for patients in CheckMate 9LA.         • A weight-based approach for nivolumab was applied based on the sponsor's assumed dosing regime of 4.5 mg and with an assumption of 5% vial sharing for nivolumab and iplimumab. The modeled dosage and vial sharing assumption did not align with the nivolumab product monograph ar led to an underestimation of the cost per dose of nivolumab.	Key data sources	CheckMate 9LA trial, CheckMate 227 trial, indirect treatment comparison (ITC; KEYNOTE trials: 189,
<ul> <li>incremental cost-effectiveness ratio when compared to the previous cost-effective treatment and the next more effective treatment)</li> <li>NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)</li> <li>Key limitations</li> <li>The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.</li> <li>Duration on treatment (DoT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicated that PFS provides an overestimation of the duration on treatment.</li> <li>For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 227 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is unclear whether outcomes for patients in CheckMate 9LA.</li> <li>A weight-based approach for nivolumab was applied based on the sponsor's assumed dosing regime of 4.5 mg per kg along with an assumption of 5% vial sharing for nivolumab product monograph ar led to an underestimation of the cost per dose of nivolumab.</li> <li>The sponsor's assumed drug prices for the chemotherapy component across comparators were</li> </ul>		
<ul> <li>Key limitations</li> <li>The CADTH Clinical Review identified several limitations with the sponsor-submitted ITC, and concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.</li> <li>Duration on treatment (DoT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicated that PFS provides an overestimation of the duration on treatment.</li> <li>For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 227 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is unclear whether outcomes for patients from CheckMate 227 can be generalized to represent long term treatment outcomes for patients in CheckMate 9LA.</li> <li>A weight-based approach for nivolumab was applied based on the sponsor's assumed dosing regime of 4.5 mg per kg along with an assumption of 5% vial sharing for nivolumab and ipilimumab. The modeled dosage and vial sharing assumption did not align with the nivolumab product monograph ar led to an underestimation of the cost per dose of nivolumab.</li> <li>The sponsor's assumed drug prices for the chemotherapy component across comparators were</li> </ul>		incremental cost-effectiveness ratio when compared to the previous cost-effective treatment and the
<ul> <li>concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH placed greater focus on the direct comparative data from CheckMate 9LA.</li> <li>Duration on treatment (DoT) in the model was assumed to equal each treatment's PFS curve. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicated that PFS provides an overestimation of the duration on treatment.</li> <li>For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 227 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is unclear whether outcomes for patients from CheckMate 227 can be generalized to represent long term treatment outcomes for patients in CheckMate 9LA.</li> <li>A weight-based approach for nivolumab was applied based on the sponsor's assumed dosing regime of 4.5 mg per kg along with an assumption of 5% vial sharing for nivolumab and ipilimumab. The modeled dosage and vial sharing assumption did not align with the nivolumab product monograph ar led to an underestimation of the cost per dose of nivolumab.</li> <li>The sponsor's assumed drug prices for the chemotherapy component across comparators were</li> </ul>		<ul> <li>NI+PDC is not among the optimal therapies (i.e., not on the efficiency frontier)</li> </ul>
<ul> <li>observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicated that PFS provides an overestimation of the duration on treatment.</li> <li>For the first 13 months, Overall Survival (OS) was modeled based on time to mortality data from the CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 227 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is unclear whether outcomes for patients from CheckMate 227 can be generalized to represent long term treatment outcomes for patients in CheckMate 9LA.</li> <li>A weight-based approach for nivolumab was applied based on the sponsor's assumed dosing regime of 4.5 mg per kg along with an assumption of 5% vial sharing for nivolumab and ipilimumab. The modeled dosage and vial sharing assumption did not align with the nivolumab product monograph ar led to an underestimation of the cost per dose of nivolumab.</li> <li>The sponsor's assumed drug prices for the chemotherapy component across comparators were</li> </ul>	Key limitations	concluded that applicability of the ITC results must be interpreted with caution. As such, CADTH
<ul> <li>CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 227 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is unclear whether outcomes for patients from CheckMate 227 can be generalized to represent long term treatment outcomes for patients in CheckMate 9LA.</li> <li>A weight-based approach for nivolumab was applied based on the sponsor's assumed dosing regime of 4.5 mg per kg along with an assumption of 5% vial sharing for nivolumab and ipilimumab. The modeled dosage and vial sharing assumption did not align with the nivolumab product monograph ar led to an underestimation of the cost per dose of nivolumab.</li> <li>The sponsor's assumed drug prices for the chemotherapy component across comparators were</li> </ul>		observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicated
<ul> <li>of 4.5 mg per kg along with an assumption of 5% vial sharing for nivolumab and ipilimumab. The modeled dosage and vial sharing assumption did not align with the nivolumab product monograph ar led to an underestimation of the cost per dose of nivolumab.</li> <li>The sponsor's assumed drug prices for the chemotherapy component across comparators were</li> </ul>		CheckMate 9LA study, thereafter, a lognormal parametric function fitted to 37 months of data from CheckMate 227 was applied for the remainder of the 20 year time horizon. According to the CADTH Clinical Review, it is unclear whether outcomes for patients from CheckMate 227 can be generalized
		modeled dosage and vial sharing assumption did not align with the nivolumab product monograph and
indocardie as they did not relieve 2020 estimates notif the RAVIA Deita I A database.		<ul> <li>The sponsor's assumed drug prices for the chemotherapy component across comparators were inaccurate as they did not reflect 2020 estimates from the IQVIA Delta PA database.</li> </ul>
<ul> <li>The sponsor's assumptions regarding drug wastage for ipilimumab (5 to 10% at large administration centers) was felt to be substantially underestimated for ipilimumab based on clinical expert and CADTH-participating drug plan feedback.</li> </ul>		centers) was felt to be substantially underestimated for ipilimumab based on clinical expert and
<ul> <li>CADTH encountered analytic limitations with the sponsor's model which applied fixed time to event distributions that limit the ability to apply stochastic analysis to these curves, limiting CADTH's ability to perform scenario analyses or test the sensitivity of the model to variations in these distributions.</li> </ul>		distributions that limit the ability to apply stochastic analysis to these curves, limiting CADTH's ability

#### Table 2: Summary of Economic Evaluation

Component	Description
	The sponsor did not include atezolizumab-based therapies as relevant comparators.
CADTH reanalysis results	<ul> <li>CADTH reanalyses included: the exclusion of the indirect comparators; using product monograph dosing for nivolumab; no vial sharing for nivolumab or ipilimumab; revised approach for modeling DoT; OS extrapolations exclusively based on CheckMate 9LA data; and revised drug prices for pemetrexed, cisplatin, carboplatin, and paclitaxel. CADTH was unable to address uncertainty associated with the sponsor's indirect treatment comparison, methodological limitations in the derivation of survival outcomes for select comparators, or the omission of relevant treatment comparators.</li> <li>NI+PDC vs. PDC: \$146,239 per QALY (incr. costs, \$73,063; incr. QALYs, 0.50)</li> </ul>
	<ul> <li>NI+PDC vs. PDC: \$146,239 per QALY (Incr. costs, \$73,063; Incr. QALYs, 0.50)</li> <li>At a WTP threshold of \$50,000 per QALY, NI+PDC had a 0% chance of being cost-effective. NI+PDC would require a price reduction of at least 28% to be considered cost-effective.</li> <li>CADTH undertook a scenario analysis to estimate the cost-effectiveness of NI+PDC compared with PDC, PEM, PEM+CHEM, and PEM+PDC. Based on the sequential analyses, NI+PDC remained extendedly dominated through PEM and PEM+PDC.</li> </ul>

ALK = anaplastic lymphoma kinase; DoT = duration on treatment; EGFR = epidermal growth factor receptor; incr. = incremental; ITC = indirect treatment comparison; LY = life-year; NI+PDC = nivolumab plus ipilimumab and two cycles of platinum-based chemotherapy; NSCLC = non-small cell lung cancer; OS = overall survival; PDC = platinum-doublet therapy; PD-L1 = programmed death ligand 1; PEM = pembrolizumab monotherapy; PEM+PDC = pembrolizumab plus platinum-doublet based chemotherapy; PEM+CHEM = pembrolizumab plus chemotherapy; PFS = progression-free survival; PSM = partitioned survival model; QALY= quality-adjusted life-year; vs. = versus

#### Conclusions

The clinical effectiveness of nivolumab plus ipilimumab in combination with platinum-doublet chemotherapy (NI+PDC) relative to other currently available treatments is limited to a direct comparison between NI+PDC and platinum-doublet chemotherapy (PDC), which suggests NI+PDC is associated with improved overall survival and progression-free survival. As there is currently no direct trial evidence that compares NI+PDC to current standards of care, specifically immunotherapy-based treatments, for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer with no known epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumour aberrations, and no high-quality indirect evidence, the relative effectiveness of NI+PDC remains unknown.

CADTH undertook reanalyses to address limitations in the sponsor's submission, including: the exclusion of indirect comparators; using a dose for nivolumab per the product monograph; an assumption of no vial sharing for nivolumab or ipilimumab; revised approach for modeling DoT; and, OS extrapolations exclusively based on CheckMate 9LA data. According to the CADTH reanalysis comparing NI+PDC versus PDC, which was exclusively based on evidence from the CheckMate 9LA trial, NI+PDC was more costly (incremental cost, \$73,063) and more effective (incremental QALYS, 0.50), yielding an incremental cost-effectiveness ratio of \$146,239 per quality-adjusted life-year gained. A price reduction of 28% is required to achieve an ICER of \$50,000 per QALY. CADTH also undertook a scenario analysis to estimate the cost-effectiveness of NI+PDC compared with PDC and other relevant comparators (pembrolizumab monotherapy, pembrolizumab plus chemotherapy, pembrolizumab plus platinum-based chemotherapy (PEM+PDC)) using the sponsor's indirect treatment comparison results. Based on a sequential analysis in this scenario; NI+PDC is extendedly dominated through PEM and PEM+PDC.

The cost-effectiveness for NI+PDC remains uncertain for patients with squamous histology, non-squamous histology, PD-L1 expression level ≥1%, or PD-L1 expression level <1%. However, NI+PDC is the most expensive treatment option available and is not likely to be considered cost-effective compared with the modeled comparators (i.e., PEM+PDC, pembrolizumab plus chemotherapy, pembrolizumab monotherapy, and PDC).

Based on the sponsor's submitted budget impact analysis, introducing NI+PDC was associated with an estimated cost saving of \$7,663,351 over the first three years. CADTH reanalyses estimated that the budget impact of introducing NI+PDC for the modelled indication could range from a saving \$83,230,349 in the first three years to an incremental cost of \$20,508,252.



### Stakeholder Input Relevant to the Economic Review

#### **Economic Review**

### **Appendix 1: Cost Comparison Table**

### **Appendix 2: Submission Quality**



## Appendix 3: Additional Information on the Submitted Economic Evaluation



### Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation



### Appendix 5: Submitted BIA and CADTH Appraisal

#### References

- pan-Canadian Oncology Drug Review. [Draft] clinical guidance report: Nivolumab-ipilimumab for non-small cell lung cancer. Ottawa (ON): CADTH; 2020. 1. Pharmacoeconomic evaluation. In: pan-Canadian Oncology Drug Review sponsor submission: Opdivo (nivolumab) and Yervoy (ipilimumab), 10 mg 2.
- nivolumab/mL in 40 mg and 100 mg single-use vials for intravenous infusion. St-Laurent (QC): Bristol-Myers Squibb Canada; 2020 Jun 23.
- 3. Final clinical study report for study: CA2099LA. A phase 3, randomized study of nivolumab plus ipilimumab in combination with chemotherapy vs chemotherapy alone as first line therapy in stage IV non-small cell lung cancer (NSCLC) [internal sponsor's report]. Lawrenceville (NJ): Bristol Meyers Squibb; 2020 Jan 21
- Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020-2031. 4 Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-5.
- cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-1830. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 6.
- 2018;378(22):2078-2092. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051. 7 Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 8.
- 2016;375:1823-1833. Ontario Ministry of Health Long-Term C. Ontario drug benefit formulary/comparative drug index. 2019; https://www.formulary.health.gov.on.ca/formulary/. 9.
- Accessed 2020 Nov 1. 10. CADTH. Keytruda for non-squamous NSCLC - details. 2019; https://www.cadth.ca/keytruda-non-squamous-nsclc-details. Accessed 2020 May 19.
- pan-Canadian Oncology Drug Review. Final clinical guidance report: pembrolizumab (Keytruda) for squamous nonsmall cell lung cancer. Ottawa (ON): 11. CADTH; 2020: https://ca fault/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC fnCGR REDACT Post 03Jan2020 final.pd Accessed 2020 May 27.
- 12. CADTH. Abraxane for metastatic pancreatic cancer - details. 2014; https://www.cadth.ca/abraxane-metastatic-pancreatic-cancer-details. Accessed 2020 Jun 9. Schedule of benefits for physician services under the Health Insurance Act: effective October 1, 2019. Toronto (ON): Ontario Ministry of Health; 2019: 13.
- http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob\_master20191001.pdf. Accessed 2020 May 19 Wehler E, Zhao Z, Bilir SP, Munakata J, Barber B. Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health 14. Econ. 2017;18(1):49-58.
- Ontario Case Costing Initiative (OCCI). Toronto (ON): Ontario Health and Long-Term Care; 2018: https://www.ontario.ca/data/ontario-case-costing-initiative-15. occi. Accessed 2020 Jun 21.
- National Institute for Health and Care Excellence. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer. 16. (Technology appraisal guidance TA347) 2015; https://www.nice.org.uk/guidance/ta347. Accessed 2020 Dec 9.
- National Institute for Health and Care Excellence. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. 17. (Technology appraisal guidance TA374) 2015; https://www.nice.org.uk/guidance/ta374. Accessed 2020 Dec 9.
- National Institute for Health and Care Excellence. Renal cancer overview. 2015; https://pathways.nice.org.uk/pathways/renal-cancer. Accessed 2020 May 22. 18 Elkrief A, Joubert P, Florescu M, Tehfe M, Blais N, Routy B. Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020. Curr Oncol. 19. 2020;27(1):52-60.
- 20. Indirect treatment comparison non-interventional study report for study CA209-9LA [Internal sponsor's report]. In: pan-Canadian Oncology Drug Review sponsor submission: Opdivo (nivolumab) and Yervoy (ipilimumab), 10 mg nivolumab/mL in 40 mg and 100 mg single-use vials for intravenous infusion St-Laurent (QC): Bristol-Myers Squibb Canada; 2020 Jun 23.
- PrOpdivo (nivolumab for injection): intravenous infusion, 10 mg nivolumab /mL 40 mg and 100 mg single-use vials [product monograph]. Montreal (QC): Bristol-21. Myers Squibb Canada 2020 Dec 3: https://pdf.hres.ca/dpd\_pm/00059094.PDF. Accessed 2020 Dec 7
- Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa (ON): CADTH; 2017: https://www.cadth.ca/dv/guidelines-economic-22. evaluation-health-technologies-canada-4th-edition. Accessed 2020 Dec 9. Budget Impact Analysis [internal sponsor's report]. In: pan-Canadian Oncology Drug Review sponsor submission: Opdivo (nivolumab) and Yervoy
- 23.
- (ipilimumab), 10 mg nivolumab/mL in 40 mg and 100 mg single-use vials for intravenous infusion. St-Laurent (QC): Bristol-Myers Squibb Canada; 2020 Jun 23. 24. Gemcitabine for injection, USP (gemcitabine hydrochloride for injection): 200 mg or 1 g gemcitabine per vial 38 mg/mL gemcitabine (as gemcitabine
- hydrochloride) sterile lyophilized powder. Toronto (ON): Generic Medical Partners Inc; 2017: https://pdf.hres.ca/dpd\_pm/00041890.PDF. Accessed 2020 Dec 9. pan-Canadian Oncology Drug Review. Final economic guidance report: pembrolizumab (Keytruda) for metastatic urothelial carcinoma (first line). Ottawa (ON): 25. CADTH; 2019: https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10177Pembrolizumab/UC%28firstline%29\_fnEGR\_NOREDACT-ABBREV\_Post\_03Oct2019\_final.pdf. Accessed 2020 May 27.